- Previous Close
12.45 - Open
12.45 - Bid 12.43 x 600
- Ask 12.46 x 100
- Day's Range
12.39 - 12.46 - 52 Week Range
5.90 - 12.48 - Volume
1,951,187 - Avg. Volume
2,138,900 - Market Cap (intraday)
796.343M - Beta (5Y Monthly) 1.40
- PE Ratio (TTM)
-- - EPS (TTM)
-2.41 - Earnings Date Apr 22, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.88
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
www.avidbio.comRecent News: CDMO
View More
Performance Overview: CDMO
Trailing total returns as of 1/23/2025, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDMO
View MoreValuation Measures
Market Cap
796.34M
Enterprise Value
968.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.26
Price/Book (mrq)
17.77
Enterprise Value/Revenue
6.44
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-101.27%
Return on Assets (ttm)
-3.05%
Return on Equity (ttm)
-115.84%
Revenue (ttm)
142.36M
Net Income Avi to Common (ttm)
-144.16M
Diluted EPS (ttm)
-2.41
Balance Sheet and Cash Flow
Total Cash (mrq)
36.78M
Total Debt/Equity (mrq)
353.77%
Levered Free Cash Flow (ttm)
-201.62k
Research Analysis: CDMO
View MoreCompany Insights: CDMO
CDMO does not have Company Insights
Research Reports: CDMO
View MoreDaily – Vickers Top Buyers & Sellers for 01/11/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/19/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What does Argus have to say about CDMO?
AVID BIOSERVICES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about CDMO?
AVID BIOSERVICES INC has an Investment Rating of SELL; a target price of $4.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target